Watch the interview with Cereno’s CEO Sten R Sörensen below:
Cereno’s CEO: ”CS014 adds potential for cardiovascular disease patients”
Cereno Scientific is a biotech company developing treatments for the number one killer in the world – cardiovascular disease. The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 – a novel epigenetic HDAC inhibitor. Cereno’s CEO Sten R Sörensen stopped by the BioStock Studio to share more details about the news.
Notiser
Paxman rapporterar stark tillväxt
Aptahem offentliggör emissionsdokument
Novo Nordisk skriver miljardavtal med Septerna
GSK köper leversjukdomsläkemedel
Fleries och Toleranzias fusion godkänd
NYHETSBREV
NYHETER
Region Skåne testar Paindrainers digitala lösning för kronisk smärta
Sanionas nye CFO: ”More deals are definitely on the horizon”
Vetenskapen bakom ColdZyme – Insikter från professorer
Kommande event!
Global Forum
Expand your understanding of new markets, striking global partnerships and attracting international capital. Find new opportunities and learn how to...
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region’s leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Du är värd det bästa!
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa konto
Krönikor
Paxman rapporterar stark tillväxt
